Pfizer and its German partner BioNTech have filed proceedings at the High Court of England and Wales, seeking a judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac’s European patents, according to a regulatory filing on Friday. In July, CureVac had filed a patent lawsuit against BioNTech over its use…
Pfizer, BioNTech Seek to Revoke CureVac’s Patent Infringement Claims
BioNTech, Pfizer Sue CureVac in US Over COVID-19 Vaccine Patent Claims
July 28, 2022
admin
BioNTechBusiness & MarketsBusinesses in COVID-19CCP VirusCompaniesCureVaceconomyPfizerVaccines & Safety
0 Comment
FRANKFURT—COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer’s COVID-19…
CureVac Files Patent Lawsuit in Germany Against BioNTech
BERLIN—CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking “fair compensation” from BioNTech and two subsidiaries for infringement…
CureVac COVID-19 Vaccine Records 48 Percent Efficacy in Final Trial Readout
CureVac said its COVID-19 vaccine was 48 percent effective in the final analysis of its pivotal mass trial, only marginally better than the 47 percent reported after an initial read-out two weeks ago. The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53 percent when excluding trial participants…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`